Abstract
MicroRNAs (miRNAs) are small conserved noncoding RNAs which function as posttranscriptional regulators of gene expression. Studies over the last 20 years have revealed the essential functions of miRNAs in regulating cardiovascular biology (such as cardiovascular cell differentiation, growth, proliferation and apoptosis) and crucial roles in controlling cardiovascular disease (CVD), indicating the potential of these small molecules as therapeutic targets and/or agents for CVD. Moreover, miRNAs in the circulation or other body fluids are stable and readily detectable, and more importantly often disease-associated, which makes them promising novel biomarkers for diagnosis and prognosis of CVDs. Furthermore, emerging evidence uncovered miRNAs as new targets and/or regulators of cardiovascular medications given the ability of miRNAs to interact with some cardiovascular drugs, which opens up new opportunities for the research and development of novel CVD drugs. Herein, we summarize current knowledge regarding the potential applications of miRNAs in the therapy of CVD, including myocardial ischemia, cardiac hypertrophy/heart failure, interstitial fibrosis, arrhythmia, diabetes and hypertension and discuss the therapeutic potential and challenge of miRNAs in drug discovery.
Keywords: MicroRNA (miRNA), drug discovery, myocardial ischemia, cardiac hypertrophy, cardiac fibrosis, arrhythmias, heart failure, hypertension, diabetes, therapy, biomarker.
Current Drug Targets
Title:MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases
Volume: 18 Issue: 4
Author(s): Pengzhou Hang, Jing Guo, Chuan Sun and Zhimin Du
Affiliation:
Keywords: MicroRNA (miRNA), drug discovery, myocardial ischemia, cardiac hypertrophy, cardiac fibrosis, arrhythmias, heart failure, hypertension, diabetes, therapy, biomarker.
Abstract: MicroRNAs (miRNAs) are small conserved noncoding RNAs which function as posttranscriptional regulators of gene expression. Studies over the last 20 years have revealed the essential functions of miRNAs in regulating cardiovascular biology (such as cardiovascular cell differentiation, growth, proliferation and apoptosis) and crucial roles in controlling cardiovascular disease (CVD), indicating the potential of these small molecules as therapeutic targets and/or agents for CVD. Moreover, miRNAs in the circulation or other body fluids are stable and readily detectable, and more importantly often disease-associated, which makes them promising novel biomarkers for diagnosis and prognosis of CVDs. Furthermore, emerging evidence uncovered miRNAs as new targets and/or regulators of cardiovascular medications given the ability of miRNAs to interact with some cardiovascular drugs, which opens up new opportunities for the research and development of novel CVD drugs. Herein, we summarize current knowledge regarding the potential applications of miRNAs in the therapy of CVD, including myocardial ischemia, cardiac hypertrophy/heart failure, interstitial fibrosis, arrhythmia, diabetes and hypertension and discuss the therapeutic potential and challenge of miRNAs in drug discovery.
Export Options
About this article
Cite this article as:
Hang Pengzhou, Guo Jing, Sun Chuan and Du Zhimin, MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases, Current Drug Targets 2017; 18 (4) . https://dx.doi.org/10.2174/1389450117666160301101221
DOI https://dx.doi.org/10.2174/1389450117666160301101221 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Plasticity of T Cell Differentiation and Cytokine Signature: A Double-Edged Sword for Immune Responses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Regulation and Quantification of Cellular Mitochondrial Morphology and Content
Current Pharmaceutical Design Exploring Newer Target Sodium Glucose Transporter 2 for the Treatment of Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Antithrombotic Treatment in Coronary Artery Disease
Current Pharmaceutical Design Therapeutic Peptides: New Arsenal Against Drug Resistant Pathogens
Current Pharmaceutical Design Obesity Related Kidney Disease
Current Diabetes Reviews Hyperuricemia and Cardiovascular Disease
Current Pharmaceutical Design The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity
Current Drug Metabolism Pharmacokinetics of Biotech Drugs: Peptides, Proteins and Monoclonal Antibodies
Current Drug Metabolism Endothelin-1 Actions on Vascular Smooth Muscle Cell Functions As a Target for the Prevention of Atherosclerosis
Current Vascular Pharmacology MiR-101 Attenuates Myocardial Infarction-induced Injury by Targeting DDIT4 to Regulate Autophagy
Current Neurovascular Research The Influence of Genetic Variations and Drug Interactions Based on Metabolism of Antidepressants and Anticonvulsants
Current Drug Metabolism The Emergent Cardiovascular Risk Factors and Organ Damage in Arterial Hypertension
Current Hypertension Reviews Hypoxia in Pre-Eclampsia: Cause or Effect?
Current Women`s Health Reviews Potential Deployment of Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type 1 and Type 2 Receptor Blockers in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Tricyclic Structures in Medicinal Chemistry: An Overview of their Recent Uses in Non-CNS Pathologies
Mini-Reviews in Medicinal Chemistry Challenges for Gene Therapy of Type 1 Diabetes
Current Gene Therapy Stem Cell Therapies
Recent Patents on Regenerative Medicine Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints
Current Pharmaceutical Design Biological Relevance of Lysophospholipids and Green Solutions for Their Synthesis
Current Organic Chemistry